Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Study of Setmelanotide in Hypothalamic Obesity

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Participants must meet all of the following criteria to be eligible for study participation:~* Participant has documented evidence of HO, including:~  * Recent evidence of hypothalamic injury on magnetic resonance imaging (MRI); AND~ * Diagnosis of craniopharyngioma or other non-malignant brain tumor affecting the hypothalamic region; AND~ * Has undergone surgery, or chemotherapy, or radiation ≥6 months and ≤15 years before Screening.~* Participant has either unilateral hypothalamic lesions or bilateral hypothalamic lesions, as assessed by MRI.~* Obesity, documented by a body mass index (BMI) ≥35 kilograms/square meter (kg/m\^2) for participants ≥18 years of age or BMI ≥95th percentile for age and gender for participants 6 to \<18 years of age.~* Documented increase in BMI (change from pre-surgery baseline in BMI z-score ≥0.2 for participants \<18 years of age or BMI \>5% for participants \>18 years of age) either during the first 6 months following surgery or within 1 year before surgery AND still present at Screening.~* More than 6 months after the end of post-tumor treatment, including chemotherapy, surgery, or radiation.~* Highly effective contraception throughout the study and for 90 days following the study.~* Ability to communicate well with the Investigator, understand and comply with the requirements of the study, and understand and sign the written informed consent, or, for participants aged \<18 years, a parent/legal guardian that can sign.~* If receiving hormone replacement therapy, the dose of such therapy has remained stable for at least 2 months prior to Screening.~Exclusion Criteria:~Participants meeting any of the following criteria are not eligible for study participation:~* Weight gain \>5% in the previous 3 months.~* Weight loss ≥2% in the previous 3 months.~* Bariatric surgery or procedure within the last 6 months.~* Diagnosis of severe psychiatric disorders~* Glycated hemoglobin (HbA1c) \>10.0% at Screening.~* Current, clinically significant pulmonary, cardiac, or oncologic disease considered severe enough to interfere with the study and/or confound the results.~* Glomerular filtration rate (GFR) \<30mL/min/1.73m\^2 during Screening.~* Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions.~* History or close family history (parents or siblings) of skin cancer or melanoma~* Participation in any clinical study with an investigational drug/device within 3 months or 5 half-lives, whichever is longer, prior to the first setmelanotide dose.~* Previously enrolled in a clinical study involving setmelanotide or any previous exposure to setmelanotide.~* Inability to comply with QD injection regimen.~* Pregnant and/or breastfeeding, or desiring to become pregnant during this trial.~* Cognitive impairment that, in the Investigator's opinion, precludes participation to the study and completions of study procedures or questionnaires.~* Participant is, in Investigator's opinion, otherwise not suitable to participate in the study.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Setmelanotide (Type: EXPERIMENTAL): Participants received setmelanotide once daily (QD) via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and dose escalated up to a maximum dose of 3.0 milligrams (mg) QD.

Based on this trial design, predict the completion outcome and termination type (if applicable).